Immunohistochemical Localization of SKALP/Elafin in Psoriatic Epidermis  by Schalkwijk, J. et al.
Immunohistochemical Localization of SKALP /Elafin 
in Psoriatic Epidermis 
J. Schalkwijk, I.M.J.J. van Vlijmen, ].A.C. Alkemade, and G.]. de lough 
Department of Dermatology, University Hospital Nijmegen, Nijmegen, The Netherlands 
Recently we have reported the purification and biochemical 
characterization of a new, inducible elastase inhibitor [skin-
derived antileukoproteinase (SKALP)], which could be ex-
tracted in high amounts from psoriatic skin but not from 
normal human skin. Here we demonstrate the immunohis-
tochemical localization of SKALP in psoriatic epidermis. 
SKALP was found exclusively in the upper layers of the 
suprabasal compartment and stratum corneum oflesional pso-
riatic epidermis. Basal keratinocytes were always negative. 
No immunoreactive SKALP was found in normal epidermis 
N eutral proteinases derived from polymorphonu-clear leukocytes (PMNs) such as elastase, cathepsin G, and proteinase-3 have been implicated in a num-ber of pathologic processes [1] , including lung em-physema [2), glomerulonephritis [3) , arthritis [4,5), 
and inflammatory skin diseases [6). Under non-pathologic condi-
tions, elastase and cathepsin G are controlled by specific high-affin-
ity proteinase inhibitors such as alpha-I-proteinase inhibitor and 
alpha-l-antichymotrypsin in plasma, and secretory leukocyte pro-
teinase inhibitor/antileukoproteinase (SLPI/ ALP), which is pro-
duced locally in mucous tissues. Recently we have described a new, 
specific elastase inhibitor in human epidermis that does not inhibit 
cathepsin G [7 - 9) . Using scales collected from patients with psoria-
sis, we purified and characterized this high-affinity inhibitor, which 
was shown to be a cationic protein with an apparent molecular 
weight of 9 to 11 kDa. There is evidence that this molecule is 
derived from an 18-kDa protein, which is found in cu ltured kerati-
nocytes and in variable amounts in psoriatic scales. Partial amino 
acid sequencing ofSKALP [8] showed homology to SLPI/ ALP [10] . 
SKALP is identical to elafin, a proteinase inhibitor which was re-
cently described by others [11], on the basis of amino acid composi-
tion and amino acid sequence data. 
Until now, only biochemical data were available on SKALP / ela-
fin, and the exact source in human skin was not clear. In this article 
we studied the cellular localization ofSKALP in psoriatic epidermis 
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Abbreviations: 
ALP: antileukoprotease 
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PMN: polymorphonuclear leukocyte 
SDS-PAGE: sodium dodecylsulfate - polyacrylamide gel electro-
phoreSis 
SKALP: skin-derived antileukoproteinase 
SLPI: secretory leukocyte proteinase inhibitor 
and non-lesional psoriatic epidermis, in accordance with find-
ings in functional assays. Western blots of skin extracts from 
psoriatic and normal skin confirmed the immunohisto-
chemical findings and revealed two major bands with appar-
ent molecular weights of 10.5 and 11.5 kDa. 
We would hypothesize that SKALP could act as a modula-
tor of epidermal inflammation by interfering with polymor-
phonuclear leukocyte trafficking, and that it could protect 
structural proteins against elastase-mediated damage.] Invest 
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using immunohistochemistry, and it is shown that only a distinct 
subpopulation of the keratinocytes expresses this molecule. 
METHODS 
Chemicals All reagents for sodium dodecylsulphate - poly-
acrylamide gel electrophoresis (SDS-PAGE) were obtained from 
Biorad laboratories, Richmond, CA. Aminoethylcarbazole, tricine, 
low - molecular-weight markers for SDS-PAGE, biotinylated 
swine-anti-rabbit immunoglobulin (Ig), avidin-peroxidase and 
avidin-conjugated alkaline phosphatase were from Sigma Chemi-
cals, St Louis, MO. Swine -anti-rabbit Ig conjugated with horserad-
ish peroxidase was obtained from Dakopatts, Glostrup, Denmark. 
Columns and materials for chromatographic purification ofSKALP 
or anti-SKALP serum were from Pharmacia, U ppsala, Sweden. This 
included polybuffer exchanger 94, cyanogen activated sepharose 
4B, protein A sepharose, a Superdex 75 FPLC-column, and a re-
verse-phase fLRPC C2/C18 column. 
Skin Biopsies Biopsies from psoriatic patients (n = 9) and nor-
mal healthy volunteers (n = 7) were taken with a keratotome or a 
razor blade, under local anesthesia, and were either fixed in buffered 
formalin or stored at -20°C until used for extraction ofSKALP. 
Permission from the local medical-ethical committee had been ob-
tained. 
Extraction of SKALP from Keratotome Slices Keratotome 
biopsies (5 to 10 mg) of psoriatic patients and healthy volunteers 
were homogenized in a glass-glass grinder in distilled water. After 
centrifugation (15 min at 12000 X g) the supernatant was boiled 
and again centrifuged. The supernatant was concentrated by vac-
uum evaporation, and subjected to SDS-PAGE and immunoblot-
ting as described below. In addition, skin extracts were used for 
functional measurementofSKALP activity (anti-elastase activity) as 
described before [7 - 9). For measurement of SKALP in the margin 
zone of the lesion, the keratotome biopsies of seven patients were 
cut in 2-mm slices, which were extracted separately and assayed for 
anti-elastase activity. 
We checked whether the total anti-elastase activity of these crude 
extracts could be attributed to SKALP, to exclude the possible inter-
ference by other elastase inhibitors such as alpha-l- proteinase in-
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hibitor and SLPI/ ALP. All elastase-inhibiting activity could be ab-
sorbed by sepharose 4B-conjugated immunoglobulins purified 
from anti-SKALP serum by protein-A chromatography. In addi-
tion, the assay conditions exclude the possible interference by 
alpha-l- prot~inase inhibitor, and the amount of SLPI/ ALP we 
found in psonatlc sk1l1 IS far lower than SKALP (less than 5%). 
Antiserum The antiserum was raised against SKALP purified 
from psoriatic scales using chromatofocusing, affinity chromatogra-
phy on immobilized pancreatic elastase, and finally Superdex-75 
gel permeation fast protein liquid chromatography as described 
previously [8]. SKALP-preparations obtained by this procedure or 
alternatively via reverse-phase chromatography on a SMART 
j1RPC-column as a final step appear to be homogeneous on chro-
matograms. However on SDS-PAGE multiple bands between 11 
and 9 kDa (apparent molecular weight) can be seen, which probably 
represent truncated and extended forms of SKALP /e1afin that were 
recently reported by Wiedow et af [12]. We could confirm these 
findings by N-terminal sequencing, which showed that our prepara-
tion contains at least three elafin forms of different length (data not 
shown) . N-terminal sequencing of a fragment generated by cleav-
age with pancreatic elastase from PVDF-blots [8] revealed substan-
tial homology of SKALP with SLPI/ ALP. However, the anti-
SKALP serum did not cross react with recombinant SLPI/ ALP as 
shown before [9]. 
The antiserum was prepared in a rabbit that was selected to be 
devoid of reactivity to normal human skin. This was a necessary 
precaution because five of six rabbits had low titers of reactivity 
against the cytoplasm of normal epidermal keratinocytes (presum-
ably keratins) or agains t basal membranes. Purified SKALP (50 ,ug) 
was crosslinked with glutaraldehyde, dialysed against distilled 
water, and emulsified with Freund's complete adjuvant. Rabbits 
were immunized intracutaneously in the back, followed by two 
subcutaneous boosters at weeks 2 and 4. Pre-immune serum was 
drawn before the experiments and immune serum was collected 
after 6 weeks. Titers in enzyme-linked immunosorbent assay were 
1/20,000. For histology, dilutions between 1/100 and 1/1,000 
were used. The antiserum was negative with extracts of normal 
human skin and human plasma proteins, on western blots. 
SDS-PAGE and Western Blotting Proteins were separated on 
a 16% polyacrylamide gel, using tricine as a trailing ion instead of 
tris-glycine [8] . Low-molecular-weight markers from Sigma were 
used : Myoglobin (16950 Da), myoglobin fragment I + II 
(14440 Da), myoglobin fragment I + III (10600), myoglobin frag-
ment I (8160), and myoglobin II (6210 Da). Gels were blotted on 
PVDF membranes and protein staining was performed with amido 
black accord ing to standard procedures. Immunologic detection of 
proteins was performed using the antiserum described above, fol-
lowed by biotinylated swine-anti-rabbit Ig and avidin-conjugated 
alkaline phosphatase. Pre-immune serum was used as a control. 
Histology Shave biopsies of human skin were fixed in buffered 
4% formalin for at least 24 h and processed for routine histology. 
Paraffin sections were made (5 ,urn) that were used for immunostain-
ing according to standard protocols. Sections were deparaffinized, 
rehydrated, pre-incubated with normal swine serum, and incubated 
with anti-SKALP serum at a dilution of 1 : 100. After incubation 
with peroxidase-conjugated swine - anti-rabbit Ig, the sections were 
developed with aminoethylcarbazole as the chromogenic substrate. 
Pre-immune serum from the immunized rabbit was used as a 
control. 
RESULTS 
Inununohistochemical Localization ofSKALP Immunohis-
tochemical staining of all normal skin specimens (n = 7) was nega-
tive (Fig 1). The same was found for the non-lesional skin (n = 7) of 
psoriatic patients (Fig 2). However, lesional psoriatic skin (11 = 9) 
revealed a subpopu lation of the epidermal keratinocytes that was 
strongly positive for SKALP (Fig 3). The upper layers of the supra-
basal compartment showed a strong cytoplasmic staining in all speci-
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Figure 1. Immunoperoxidase staining of normal human skin with poly-
clonal anti-SKALP. Counterstained with hematoxylin and eosin. Bar, 
50,u . No positive staining was found. The darker cells are melanin con-
tailing basal cells (arrows) and cells of the granular layer that pick up the 
counterstaining more intensely than the other cells (arrowheads). 
mens studied, with minor interpatient variation. Staining of the 
upper parakeratotic layers and the stratum corneum varied from 
mild to strong. The wall of the cornified envelope was often found 
to be strongly positive, suggesting that SKALP is to some extent 
crosslinked to the envelope proteins. No staining of basal cells or 
dendritic cells was observed in the epidermis. Also the dermal tissue 
was c.ompletely negative. The control (pre-immune) serum was 
negative Wlt~ all tissue samples studied (not shown). These immu-
nohistochemical findmgs correlate with previous findings on th e 
presence ofSKALP 1I11l0rmal and psoriatic skin as determined with 
a functiona l biochemical assay [7]. 
. The margin zOlle of the spreading psoriatic lesion is of particular 
mterest because early pathogenetic events can be detected in this 
~rea. PrevJous studies [13] have shown that the pronounced changes 
111 the leslOnal epidermiS (such as parakeratosis , cytokeratin 16 ex-
Figure 2. Uninvolved skin of a psoriatic patient. Staining as indicated in 
Fig 1. No positive staining was seen. The apparent staining of the basal 
cell layer is caused by melanin (arrows) . Bar, 50 J1.. 
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Figure 3. Lesional psoriatic skin, stained with polyc1onal anti-SKALP 
serum. Note the strong, positive staining of the suprabasal keratinocytes. 
Also the cornified envelopes in the stratum corneum are stained. Hema-
toxylin and eosin counterstaining. Bar, 50 11· 
pression, Ki-67 binding) show a clear transition to clinically unin-
volved skin. It was found that SKALP expression declined when the 
morphology of the epidermis became normal (no acanthosis, no 
parakeratosis, and a well-developed granular layer). The transition, 
however, is nor sharp. In Fig 4, a biopsy taken from the margin zone 
is shown. Positive staining for SKALP is seen in the suprabasal cells 
of the lesional part of the biopsy where acanthosis and scaling are 
visible and a granular layer is absent. At the other end of the biopsy 
no positive staining for SKALP is present; here the epidermal thick-
ness is nearly normal and a well-developed granular layer is present. 
The immunohistochemical distribution correlated with previous 
findings in biochemical assays. SKALP activity in the lesion was 
302 ± 182 units per mg, in the margin zone 52 ± 37 units per mg, 
and just outside the lesion in the clinically uninvolved skin 4 ± 4 
units per mg tissue (mean of seven keratotome biopsies ± SD). 
Western Blots of Skin Extracts The presence of SKALP in 
lesional psoriatic skin could also be demonstrated on Western blots. 
Extracts of keratotome biopsies were subjected to SDS-PAGE and 
blotted on PVDF membrane. Staining with anti-SKALP revealed 
two major bands of approximately 10.5 and 11.5 kDa, using the 
Sigma low - molecular-weight standards (Fig 5). The staining pat-
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
tern matches the pattern found for SKALP found in urine [9]. In 
SKALP preparations from psoriatic scales usually more heterogene-
ity in molecular weight is found. Normal human skin and non-
lesional psoriatic skin were negative for SKALP (not shown). The 
pre-immune serum was negative with all tissues studied. 
DISCUSSION 
In this article we demonstrate that SKALP / elafin, a new epidermal 
elastase inhibitor that was recently described by two groups at the 
biochemical level [7,11], is localized in the epidermal keratinocyte 
of psoriatic skin. In accordance with previous functional assays [7], 
no SKALP could be demonstrated in normal human epidermis. 
Surprisingly, SKALP is only expressed in the suprabasal cells; basal 
cells are completely negative. The pattern of expression resembles 
the pattern found for differentiation-related proteins in psoriatic 
skin such as involucrin and transglutaminase [14] . A difference with 
these molecules is the fact that SKALP is lacking in normal skin, 
whereas involucrin and transglutaminase are expressed in the gran-
ular layer of normal skin but are prematurely expressed in the spi-
nous layers of psoriatic skin. 
Originally, SKALP /Elafin was purified from psoriatic scales, and 
Wiedow et al [11] initially reported a molecular weight of70l7 for a 
57 -amino-acid molecule, as determined by N-terminal gas-phase 
sequencing. Recently Wiedow et al reported that at least five forms 
of elafin existed due to N-terminal deletions and extensions of the 
original 57 - amino-acid molecule [12] . We have also consistently 
found heterogeneity in scale preparations; even SKALP prepara-
tions that appear pure on reverse-phase chromatography were 
found to contain mixtures of at least three SKALP peptides (not 
shown). As shown in this paper, in extracts of psoriatic epidermis 
(with only a minimal amount of scale present) two major bands of 
approximately 10.5 and 11.5 kDa are present. A similar finding was 
previously reported for urine from psoriatic patients [9]. In previous 
papers we reported the presence ofSKALP in cultured human kerati-
nocytes, with an apparent molecular weight of 18 kDa. We have 
recently completed the purification and N-terminal sequencing of 
this protein, which is indeed identical to SKALP / elafin but contains 
an additional 38 amino acids at the N-terminal side compared to the 
original 57 -amino-acid molecule. These findings were confirmed 
at the cDNA level (Molhuizen el ai, manuscript in preparation). 
Interestingly the elongated form of SKALP / elafin contains multi-
ple motifs that are a consensus sequence for trans glutaminase cross-
linking. This might explain the immunohistochemical observation 
that SKALP is associated with the cornified envelope (see Fig 3). 
Although there is now firm evidence for a role of the keratinocyte 
in the initiation of inflammation [15], little is known about the 
mechanisms that control inflammation. In this paper we demon-
strate that epidermal keratinocytes can produce a proteinase inhibi-
tor that could act as an off-switch mechanism for the acute (PMN-
dependent) phase of cutaneous inflammation. We have shown that 
Fi.gure 4: . Biops~ f~om the margin. zone of a psoriatic lesion, stained with anti-SKALP serum. On the left hand side a typical psoriatic morphology is seen 
With positIVe stammg for SKALP m the upper spmous layers (arrows). On the right hand side the morphology resembles that of normal skin with little 
acanthosis and a well-developed granular layer (arrow/leads). No positive staining for SKALP in the spinous layer is found. Hematoxylin and eosin 
counterstaining. Bar, 50 11 . 
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Figure 5. Wester:' blot of proteins ~xtracted from psori.atic lesional skin. 
Latle 1, staining with polyclonal anti-SKALP; lalle 2, premunune (control) 
serum; lalle 3, Amido black staining of blotted proteins; lalle 4, marker 
proteins. Molecular weights in kDa . 
SKALP is a molecule not present in normal skin. However, S~LP 
can be induced in normal skin followin g injury, and it is found m the 
lesional skin of psorias is and o ther inflammatory dermatoses [7,16]. 
Specul atively, SKALP could functio n as an inhibitor of PMN mi-
gration and provide protection against elastase-mediated damage. 
SKALP could control the proteolysis of structural protems m the 
epidermis (e.g ., desm osomes) thereby preventing intraepidermal 
b lister formation. It is very likely that SKALP also reaches the der-
mal compartment, because we have recently demonstrated SKALP 
in urine of psoriatic patients that is presumably derived from the 
epidermis [9] . Therefore, SK!'LP could also protect the dermal 
elas tin fibers agamst pro teolytiC attack. . . 
These findings suggest a novel and intriguing contnbutlon of 
keratinocytes in the regulation of cutaneous inflammarory proc-
esses. 
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